MDMA-Assisted Psychotherapy in Veterans With Combat-Related, Refractory PTSD
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This will be a single-site, open-label phase 2 study designed to test the feasibility of
administering MDMA in conjunction with psychotherapy for combat-related treatment-resistant
PTSD in US military veterans currently enrolled in VA. MDMA will be given in conjunction with
structured psychotherapy in three single-dose psychotherapy sessions in a hospital setting
over the course of 12 weeks, along with preparatory and integration psychotherapy sessions
in-between each active-dose session. The overall objective of this study is to evaluate the
risks, benefits, and feasibility of MDMA used in conjunction with manualized psychotherapy,
on reduction of symptoms, or remission of PTSD, as evaluated by standard clinical measures,
in a VA Healthcare System.
The primary outcome measure for the study is the Clinician-Administered PTSD Scale (CAPS-5),
a semi-structured interview used in the majority of clinical trials for PTSD, which will be
assessed at baseline, primary endpoint, and at the long-term 12-month follow-up visit.
Secondary safety and efficacy measures will also be collected.
The planned duration of this study is 1-3 years, with each active treatment period lasting
approximately 12 weeks, along with a long-term follow-up 12 months after the last active-drug
session.
Phase:
Phase 2
Details
Lead Sponsor:
VA Loma Linda Health Care System
Collaborator:
Multidisciplinary Association for Psychedelic Studies